Skip to main content

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Calithera Biosciences, Inc.

Start Date

April 2, 2019

End Date

April 20, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Calithera Biosciences, Inc.

Start Date

April 2, 2019

End Date

April 20, 2024